Previous Article | Next Article 
Journal of Clinical Microbiology, February 1998, p. 427-436, Vol. 36, No. 2
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Impact of Strain Heterogeneity on Lyme Disease
Serology in Europe: Comparison of Enzyme-Linked Immunosorbent Assays
Using Different Species of Borrelia burgdorferi Sensu
Lato
Ulrike
Hauser,1,*
Heide
Krahl,1
Helmut
Peters,2
Volker
Fingerle,1 and
Bettina
Wilske1
Max von Pettenkofer-Institut für
Hygiene und Medizinische Mikrobiologie,
Ludwig-Maximilians-Universität München, D-80336
Munich,1 and
Behring Diagnostics GmbH,
D-35001 Marburg,2 Germany
Received 20 June 1997/Returned for modification 31 July
1997/Accepted 4 November 1997
 |
ABSTRACT |
For the standardization of serological tests for Lyme borreliosis
(LB) in Europe, the influence of the heterogeneity of Borrelia burgdorferi sensu lato must be assessed in detail. For this study four immunoglobulin M (IgM) and IgG enzyme-linked immunosorbent assays
(ELISAs) with octyl-
-D-glucopyranoside extracts of
strains PKo (Borrelia afzelii), PBi (Borrelia
garinii), and PKa2 and B31 (both B. burgdorferi sensu
stricto) were compared. Strains PKo, PBi, and PKa2 at the passages used
for antigen preparations abundantly expressed outer surface protein C
(OspC), whereas strain B31 at the passage used for antigen preparation
did not express OspC. Sera (all from Germany) from 222 patients with
clinically defined LB of all stages, 133 blood donors, and 458 forest
workers were tested. None of the forest workers had symptoms consistent
with LB at the time that the samples were collected. For IgM tests, receiver operating characteristic curves demonstrated that
discrimination between sera from patients and blood donors was best
with strain PKo and worst with strain B31. The discriminatory abilities
of the four IgG ELISAs were similar in a diagnostically reasonable specificity range (90 to 100%). More than 20% of the sera from forest
workers reacted strongly in the PKo IgG ELISA (optical density value,
>1.5; other assays, less than 8%). Western blots of the sera with the
most discrepant ELISA results revealed almost exclusive reactivity with
p17. This highly immunogenic antigen is only expressed by strain PKo.
This observation might be important for the development of assays
enabling discrimination between asymptomatic or previous infection and
active disease.
 |
INTRODUCTION |
Lyme borreliosis (LB) is a global
tick-associated disease caused by infection with Borrelia
burgdorferi sensu lato. The disorder develops in stages and has
different manifestations. In Europe, three species pathogenic for
humans (2) and at least eight serotypes of B. burgdorferi sensu lato (40, 44) demonstrating both
inter- and intraspecies heterogeneity are known. Different species seem
to show a preferential association with different clinical
manifestations (1, 35, 44). The most frequent disorders in
Eurasia are erythema migrans (EM) localized around the tick bite
lesion, neuroborreliosis (NB), acrodermatitis chronica atrophicans
(ACA), and arthritis (19, 32). In Europe, all three
pathogenic species have been isolated from human biopsy specimens and
cerebrospinal fluid (CSF) as well as from ticks (Ixodes
ricinus), but the predominant species seem to be Borrelia afzelii and Borrelia garinii. B. afzelii has been found
to be associated more frequently with skin lesions, whereas B. garinii is the predominant species found in patients with
neurological disorders (8, 35, 40, 44). In North America
only B. burgdorferi sensu stricto occurs (30,
44); arthritis occurs frequently, whereas ACA is almost unknown,
and multiple EM lesions are more common in North America than in Europe
(33).
The diagnosis of Lyme disease is based on the recognition of typical
clinical signs and is supported by laboratory tests, especially if the
clinical picture is not clear. Since culture is laborious and
insensitive and PCR assays are still considered controversial, routine
testing comprises mostly serological methods. However, serology also
harbors several problems: The occurrence of cross-reacting antibodies
may result in false-positive findings (5). Furthermore,
patients may still be seronegative in the early stages of the infection
and the humoral immune response can be diminished after the early onset
of antibiotic treatment (37). Several strategies for
increasing both sensitivity and specificity (i.e., the discriminatory
ability of the test) have been developed, for instance, preabsorption
of cross-reactive antibodies with Treponema phagedenis
(49), the use of detergent extracts of B. burgdorferi sensu lato (3), and the use of purified flagella (16) or various recombinant antigens (7, 31,
41, 42).
Serological tests for Lyme disease have not been standardized so far,
leading to considerable variations in test results among different
laboratories. The heterogeneity of Lyme disease borreliae as well as
different methods of antigen preparation and test performance may
contribute to the problem.
In Europe, the extent of variation resulting from the use of different
strains for antigenic preparations is still widely discussed (1,
23, 46, 48). Differences in the regional distributions of
borrelial species may further influence the preferential reactivities
of sera from patients with LB (6, 26).
In this study, enzyme-linked immunosorbent assays (ELISAs) with
detergent extracts of different strains representing the three species
pathogenic for humans were compared. Strains PKo (B. afzelii), PBi (B. garinii), and PKa2 (B. burgdorferi sensu stricto) at the passage used to obtain coating
antigens abundantly expressed outer surface protein C (OspC), whereas
strain B31 (B. burgdorferi sensu stricto) at the passage
used to obtain coating antigen did not express OspC. In Western blot
studies OspC has been shown to be one of the most immunodominant
antigens for the early immune response (12, 13, 17, 48). The
influence of the expression of this lipoprotein on the results of
ELISAs was especially monitored by comparison of the test results for
the otherwise closely related B. burgdorferi sensu stricto
strains PKa2 and B31 (20, 29, 38, 43). To analyze the
sensitivities and specificities of the four ELISAs, we probed sera from
German patients with different clinical manifestations as well as sera
from healthy blood donors and forest workers (as an example of a group
highly exposed to ticks and at high risk of contracting infections with
B. burgdorferi sensu lato).
 |
MATERIALS AND METHODS |
Sera.
Sixty-six serum specimens from unselected, untreated
patients with EM were obtained by a dermatologist during a previous
multicenter therapy study (37). The median time period
between the appearance of EM and collection of the serum samples was 3 weeks (range, 1 day to 31 weeks). The sera were collected from patients
throughout Germany during the years 1989 through 1991 during the months
April through January. The NB group (n = 125) included
38 patients (designated NB I) from whom B. burgdorferi sensu
lato was isolated from CSF and 87 other patients (designated NB II)
with typical signs of acute NB, CSF pleocytosis, and specific
immunoglobulin G (IgG) CSF/serum indices of >2.0 determined by an
in-house ELISA with strain PKo (39). All serum specimens
were obtained on the same days that the CSF specimens were obtained.
The median durations of neurological symptoms prior to obtaining the
serum samples was 3 weeks in both NB groups (range, 1 day to 1 year).
These sera were collected during the years 1984 through 1995 during the
months May through January (72 serum specimens were obtained in August
or September). The patients came from throughout Germany, but most were
from the south. Thirty-one serum specimens were obtained from patients
with ACA diagnosed by a dermatologist. Samples were collected during
the years 1988 through 1995 with no seasonal dependence. The patients
came from throughout Germany, but most were from the south. Sera
(n = 458) from healthy forest workers from Bavaria
(southern Germany) were collected during a former study (25)
during the years 1984 and 1985. Sera from 133 blood donors were
investigated for determination of cutoffs. Samples were obtained in
December 1990 from a Munich blood bank. The whole of Germany is a
region where LB is endemic. All sera were stored in aliquots at
20°C.
Preparation of antigens.
Borrelial strains PKo (B. afzelii; OspA serotype 2), PBi (B. garinii; OspA
serotype 4), PKa2 (B. burgdorferi sensu stricto; OspA
serotype 1), and B31 (B. burgdorferi sensu stricto; OspA serotype 1) (44) were used for antigen preparations. Strains PKo, PBi, and PKa2 have been isolated from German patients at the Max
von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie, Munich; PKo was isolated from skin (EM), and PBi and
PKa2 were cultured from CSF. Strain B31 was obtained from W. Burgdorfer
(Hamilton, Mont.). Strains were grown in modified Kelly medium
(28) at 33°C for 4 to 5 days and were harvested at a cell
density of 107/ml. The protein concentration of the final
suspension was estimated by the Bradford (4) protein assay
(Bio-Rad, Munich, Germany). The preparation was stored at 20°C.
Low-passage strains (approximately 25 passages) PKo, PBi, and PKa2
abundantly expressed OspC, whereas the high-passage strain B31 did not.
This was shown by Coomassie brilliant blue staining after sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) as well
as by probing with the OspC-specific monoclonal antibody L22 1F8
(45). If OspC had been expressed by the passage of B31 used,
it would have been recognized by L22 1F8 (43).
ELISAs.
Microtiter plates were coated with whole-cell
octyl-
-D-glucopyranoside (OGP) extracts of the
respective antigen preparations (27). The concentrations of
the coating antigens were optimized for the best matching of the
different strains by using a representative panel of human sera (11 individual serum samples from German patients and blood donors; 5 were
IgG negative, and 6 were IgG positive). The protein concentration (0.5 to 3 µg/ml) was not identical for each strain, since coating was
optimized for each strain by antigen titration to obtain the best
correlation of signals. Plates were coated identically for both IgG and
IgM tests, and all assays were performed with the same batch of plates.
Assays were performed separately for IgG and IgM, according to the
manufacturer's instructions for the commercial PKo ELISA, by using a
Behring ELISA processor III (Enzygnost Borreliosis; Behring
Diagnostics, Marburg, Germany). The sample diluent contained
ultrasonicated cell lysates of T. phagedenis for absorption
of cross-reacting antibodies. All sera were evaluated twice (in the
same microtiter well), and testing was repeated if these readings
differed by more than 10% for optical density (OD) values greater than
0.150. A weakly positive serum sample used as a calibrator and one
negative serum sample were processed in duplicate on each plate. The
mean of all readings for the calibrator serum sample throughout the
study was determined. Interassay variability was compensated for by
using a correcting factor obtained by dividing this mean by the actual
OD value. Mean OD values for the calibrator serum sample were between
0.613 and 0.863 for the different assays, and correcting factors ranged from 0.719 to 1.297. For the commercial PKo assay, the intra- and
interassay coefficients of variation are usually less than 15% for
positive samples, and the assays with the other strains were produced
and run in exactly the same way. Quantification of specific IgG has
been established for the PKo assay (27).
SDS-PAGE and WB.
Western blotting (WB) was performed and the
results were interpreted as previously described in detail
(17). Briefly, a cell lysate was electrophoresed
(22) by using 12.5% polyacrylamide gels 17 cm in length.
Proteins were transferred to nitrocellulose (Schleicher & Schuell,
Dassel, Germany) by semidry blotting (21). After blocking of
unspecific binding sites, the membranes were incubated in sera diluted
1:200 for the IgG WB and 1:100 for the IgM WB, washed, and incubated
with horseradish peroxidase-conjugated anti-human IgG and IgM
antibodies, respectively (Dakopatts, Copenhagen, Denmark) (dilutions,
1:1,000 for IgG and 1:500 for IgM). Color was developed by adding
diaminobenzidine and H2O2.
The following interpretation criteria for a positive WB result were
used: for IgG WB, at least two bands of p83/100, p58, p43, p39, p30,
OspC, p21, p17, and p14 for PKo, at least one band of p83/100, p39,
OspC, p21, and p17b for PBi, and at least one band of p83/100, p58,
p56, OspC, p21, and p17a for PKa2; for IgM WB, at least one band of
p39, OspC, and p17 or a strong p41 band for PKo, at least one band of
p39 and OspC or a strong p41 band for PBi, and at least one band of
p39, OspC, and p17a or a strong p41 band for PKa2 (17).
Statistics.
When appropriate, the results were analyzed by
McNemar's
2 test (paired proportions) or Fisher's
exact test (independent proportions). All statistical tests were
performed in a two-sided manner.
Receiver operating characteristic (ROC) curves, which are plots of
1

specificity versus sensitivity (false-positive rate
versus
true-positive rate), were constructed for all ELISAs. Specificity
levels were based on various cutoff values obtained from percentile
calculations for 133 blood donors; the respective sensitivities
were
determined by testing 222 serum samples from patients with
LB. The
discriminatory ability of each assay is represented by
the area between
the diagonal line from 0/0 to 1/1 and the respective
ROC curve
(
11).
Spearman rank correlation coefficients were determined (OD values were
not normally distributed) to analyze the correlation
of the OD values
from the different ELISAs (
11).
 |
RESULTS |
Preparation of antigens.
As demonstrated in Fig.
1, strains PKo, PBi, and PKa2 abundantly
expressed OspC at the passages used, whereas strain B31 completely lacked this antigen at the passage used. OGP extracts of these whole-cell lysates were used as antigenic coatings.

View larger version (114K):
[in this window]
[in a new window]
|
FIG. 1.
Coomassie brilliant blue-stained SDS-polyacrylamide gel
demonstrating the antigenic preparations used for ELISAs. Lanes M,
molecular mass marker; lane 1, whole-cell lysate of strain PKo
(B. afzelii); lane 2, whole-cell lysate of strain PBi
(B. garinii); lane 3, whole-cell lysate of strain PKa2
(B. burgdorferi sensu stricto); lane 4, whole-cell lysate of
strain B31 (B. burgdorferi sensu stricto); lane 5, OGP
extract of strain PKo; lane 6, OGP extract of strain PBi; lane 7, OGP
extract of strain PKa2; lane 8, OGP extract of strain B31. The OGP
extracts in lanes 5 to 8 were used as antigenic coatings. The OspC
bands of strains PKo, PBi, and PKa2 are indicated on the left. Strain
B31 did not express OspC. Numbers on the right indicate the molecular
masses of the marker proteins (in kilodaltons).
|
|
Definition of cutoff values.
Sera (n = 133)
from blood donors were tested, and the OD values of all sera were
sorted separately for each test for the determination of percentiles
(Fig. 2). The 10 most strongly reacting
serum samples in the IgG ELISAs and the 18 most strongly reacting serum
samples in the IgM ELISAs were subsequently tested by WB with
whole-cell lysates of the respective strains. Most sera were either
positive or showed reactions with unspecific bands (for IgG WB with
PKo, 6 positive and 3 unspecific serum samples; for IgG WB with PBi, 5 positive and 4 unspecific serum samples; for IgG WB with PKa2, 6 positive and 2 unspecific serum samples; for IgM-WB with PKo, 6 positive and 10 unspecific serum samples; for IgM WB with PBi, 7 positive and 8 unspecific serum samples; for IgM WB with PKa2, 5 positive and 9 unspecific serum samples). Between the 92nd and 100th
percentiles the OD values of the IgG ELISAs increased considerably, whereas in the IgM ELISAs a gradual increase was observed. The OD
values of the 92nd and the 95th percentiles were defined as cutoffs for
the IgG and the IgM assays, respectively (Table
1). For simplification, no borderline or
retest ranges were defined in this study.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 2.
Results of ELISAs with OGP extracts of the four strains
for sera from 133 blood donors. The resulting OD values were sorted in
increasing order for the determination of percentiles. Percentiles
taken as cutoff values are indicated by broken lines (92nd percentile
for IgG tests, 95th percentile for IgM tests).
|
|
ROC curves.
The discriminatory abilities (between patients and
controls) of the four ELISAs were analyzed by ROC curves (Fig.
3). By this method, the properties of a
diagnostic assay can be analyzed without reference to an individual
(arbitrary) cutoff. For IgG tests the largest ROC areas resulted for
the B31 ELISA, but in the specificity range of between 90 and 100%,
which is conclusive for diagnostic purposes, the differences in the
sensitivities of the four assays strongly depended on the specificity
level. For example, at 92% specificity, the highest sensitivity was
achieved with the PKo ELISA (PKo ELISA, 68%; PBi ELISA, 65%; PKa2
ELISA, 57%; B31 ELISA, 63%), whereas at 97% specificity, the PKo
ELISA was the least sensitive (PKo ELISA, 39%; PBi ELISA, 46%; PKa2
ELISA, 50%; B31 ELISA, 53%). For IgM tests the ROC area of the PKo
ELISA was the largest and the ROC area of the B31 ELISA was the
smallest, meaning that the PKo test gave the best discrimination and
the B31 test gave the worst.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 3.
ROC curves for different ELISAs. Specificity levels were
based on various cutoff values obtained from percentiles for sera from
133 blood donors; the respective sensitivities were determined by
probing 222 serum samples from patients with LB. The diagonal line (0/0
to 1/1) represents a completely uninformative test. The discriminatory
ability of each assay is represented by the area between this line and
the respective ROC curve. (A) ROC curves for IgG ELISAs. Broken lines,
sensitivities at 92.5 and 97% specificity. (B) ROC curves for IgM
ELISAs.    , PKo;      ,
PBi;         , PKa2; ______,
B31.
|
|
Sensitivities for different study groups.
Subsequently, the
sensitivities of the four ELISAs were determined separately for all
study groups (Table 2). Whenever
possible, differences between ELISAs were analyzed by McNemar's
2 test.
For NB I, similar sensitivities were obtained by the PKo, PBi, and PKa2
ELISAs, but the sensitivities of the B31 ELISAs were
lower. However,
since no more than 38 samples were available for
this group (a positive
culture of CSF was required), these differences
were insignificant. By
testing for both IgG and IgM, 73.7% (B31
ELISA) to 84.2% (PKa2 ELISA)
of the sera were found to be positive.
For NB II, the PKo tests were
the most sensitive, followed by
the PBi, PKa2, and B31 tests, in
decreasing order.
The best strain for the detection of antibodies in patients with EM
lesions was PKo. The PBi and PKa2 ELISAs showed similar
results, while
the results of the B31 IgG ELISA were comparable
to those of the PKo
IgG assay, but the B31 IgM ELISA was the least
sensitive of the four
IgM tests. By testing for both IgG and IgM,
62.1% (PBi and PKa2
ELISAs) to 75.8% (PKo ELISA) of the sera were
positive.
All sera from patients with ACA were reactive in all four IgG ELISAs.
IgM antibodies could be detected in 9.7% (B31 ELISA)
to 48.4% (PKo
ELISA) of the patients with ACA.
The sera from the forest workers were more frequently reactive in IgG
ELISAs with PKo or PKa2 than in IgG ELISAs with PBi
or B31. IgM tests
were positive for 1.1% (B31 ELISA) to 12.0%
(PKo ELISA) of the forest
workers. A total of 41.5% (B31 ELISA)
to 46.9% (PKo ELISA) of the
sera were positive by evaluation by
both IgG and IgM tests.
Correlation of OD values of different ELISAs.
To demonstrate
correlations of ELISA results, OD values from different assays were
plotted against each other (Fig. 4 and 5). In IgG tests (Fig. 4) with sera from patients with NB the highest
correlations occurred between the PKo, PBi, and PKa2 ELISAs (all
Spearman rank correlation coefficients, r values, greater than 0.96). The correlation coefficients of the plots between ELISAs
with each of the last three strains and the ELISA with strain B31 were
between 0.84 and 0.87. For the groups of forest workers as well as
patients with skin manifestations (EM and ACA), results of tests with
strains PBi, PKa2, and B31 correlated better (r values,
greater than 0.95 for all correlations) than the PKo ELISAs with any of
these other assays (r values, between 0.84 and 0.93). This
scattering resulted from the fact that several sera from these groups
were considerably more reactive with PKo than with the other strains.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 4.
Plots of OD values of the different IgG ELISAs against
each other. Continuous lines, cutoff OD values for the respective
assays. r values, Spearman rank correlation coefficients.
|
|
In IgM tests (Fig.
5) with sera from all
patients with LB (both neurological and skin manifestations), the best
correlations
were found between PKo, PBi, and PKa2 ELISAs (
r
values, between
0.84 and 0.96). The scattering was wider in the plots
of the data
for the B31 ELISA against the data for the ELISAs with each
of
the other strains (
r values, between 0.57 and 0.74). In
tests
with the sera from the forest workers,
r was between
0.61 (PKo
ELISA versus B31 ELISA) and 0.80 (PBi ELISA versus PKa2
ELISA).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 5.
Plots of OD values of the different IgM ELISAs against
each other. Continuous lines, cutoff OD values for the respective
assays. r values, Spearman rank correlation coefficients.
|
|
WB of selected sera.
Several sera which had shown discrepant
reactivities in ELISAs with different antigens were further examined by
WB to identify the individual antigens which were recognized. Since
most serum samples did not show such discrepant reactivities, this
selection does not represent the respective study groups, with the
exception of some of the sera from forest workers and patients with
ACA. Examples of some results are presented in Fig.
6. Serum samples A (from a patient with
NB) and B (from a patient with EM) showed preferential IgM reactivity
with OspC from PBi. Serum sample C (from a patient with NB) reacted
with p41 of PKa2 and PBi but not with p41 of PKo, whereas serum sample
D (also from a patient with NB) reacted almost only with p17 of PKo
(both serum sample C and serum sample D were tested by WB for IgG).
Serum samples E and F were obtained from a patient who had had an ACA 5 years previously (serum sample E) and a forest worker (serum sample F).
They both showed remarkable preferential IgG reactivity with PKo, and
the most immunodominant protein was p17. An additional 22 serum samples
from forest workers, which were selected due to their predominant IgG
reactivities with PKo, were also strongly reactive with p17 by WB.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 6.
Western blots with six selected serum samples with
reproducible discrepant reactivities by ELISA. OD values for the
different ELISAs are given in parentheses. (A) Serum from a patient
with NB; IgM (PKa2, 0.252; B31, 0.334; PKo, 0.294; PBi, 0.728). (B)
Serum from a patient with EM; IgM (PKa2, 0.325; B31, 0.437; PKo, 0.709;
PBi, 0.898). (C) Serum from a patient with NB; IgG (PKa2, 0.412; B31,
0.325; PKo, 0.182; PBi, 0.353). (D) Serum from a patient with NB; IgG
(PKa2, 0.153; B31, 0.062; PKo, 0.849; PBi, 0.135). (E) Serum from a
patient who had had ACA 5 years previously; IgG (PKa2, 0.296; B31,
0.092; PKo, 2.687; PBi, 0.659). (F) Serum from a forest worker; IgG
(PKa2, 0.323; B31, 0.213; PKo, 2.479; PBi, 0.327). Lanes 1, PKa2; lanes
2, PKo; lanes 3, PBi; lanes M, molecular mass marker. The numbers on
the left indicate the molecular masses of the marker proteins (in
kilodaltons). The most important immunodominant proteins are indicated
on the right.
|
|
Elevated specific IgG concentrations in patients with clinical
manifestations and asymptomatic infections.
The significance of OD
values in different ranges of the four IgG ELISAs is demonstrated in
Table 3. The percentages of sera with OD
values greater than three arbitrarily defined levels (ODs of >0.5,
>1.5, and >2.5) were determined for the patients with clinically
defined LB as well as for the forest workers. The PKo ELISA showed no
significant differences between these two groups (P > 0.05). However, in assays with all other strains, significantly higher
percentages of sera from patients with LB were strongly reactive in
comparison to the sera from forest workers (P < 0.01 for most comparisons).
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Significance of elevated titers in sera from patients
with LB versus sera from healthy forest workers by different
IgG ELISAs
|
|
 |
DISCUSSION |
Definition of cutoff values.
A basic precondition for the
comparison of sensitivities of different tests is the definition of
cutoff values. The 133 blood donors whom we tested for this purpose
came from southern Bavaria, where Lyme disease occurs relatively
frequently (19, 25) (incidence and prevalence are not known
exactly, but on average, 12.6% [15] of the ticks in
this area have been shown to be infected with B. burgdorferi
sensu lato). The sera were obtained from a blood bank, and therefore,
exclusion of samples from persons with a history of LB was not
possible. Considering the remarkably higher IgG reactivities of a few
of these serum specimens (Fig. 2), which were mostly confirmed by WB,
it was assumed that these sera might represent samples from persons
with prior infections. Thus, the cutoff OD values for the IgG ELISAs
were defined by the 92nd percentile and not by the 95th percentile, as
usual. Furthermore, cutoff values must provide a realistic basis for
the comparison of the four assays, and the OD values between the 92nd
and the 100th percentiles seemed to be much more strongly influenced by
chance (Fig. 2). Since IgM reactivity reflects early disease, which
presumably occurs comparably less frequently in a general population,
the cutoffs for the IgM tests were defined by the 95th percentile. The
resulting cutoff levels suitably reflect the differences in the four
ELISAs. These differences might result from minor variations in the
plate coatings as well as from the general preferential reactivity of
the sera from the blood donors representing the local population.
In principle, this percentile method may lead to rather arbitrary
results. Just a few samples from the blood donor panel are
critical for
the outcome of the whole study (unless thousands
of sera are probed
only for the definition of cutoffs). This problem
can be demonstrated
very clearly by the analysis of ROC curves.
However, because all other
methods are arbitrary as well, we retained
it.
ROC curves.
The ROC curves for IgG tests (Fig. 3A) indicate
that the best overall discrimination between sera from patients with LB
and controls was achieved with B31 from the passage at which it lacked OspC. OspC is an early antigen which can also be recognized by unspecific antibodies at a very low level (13). Perhaps this could explain the lower background reactivity of the B31 IgG ELISA. However, the greatest distances between the four ROC curves were observed at specificity levels lower than 90%, which are not useful for diagnostic purposes. Regarding the section between 90 and 100%
specificity, the curves are considerably more similar. Comparison of
individual specificity levels, however (for example, 92 and 97%),
leads to large variations in the differences in sensitivities between
different tests. This clearly demonstrates the consequences of using
arbitrarily defined cutoff levels.
For IgM ELISAs, the best discrimination was achieved with PKo and the
worst was achieved with B31 (Fig.
3B). From Fig.
2 it
is evident that
97% of the sera from blood donors had remarkably
low OD values in the
IgM PKo ELISA. On the other hand, by regarding
the high degrees of
correlation of the OD values from different
IgM assays (Fig.
5), it
seems as if the high sensitivity obtained
with PKo might be caused by
the relatively low cutoff. However,
since all assays with the four
antigen preparations were run in
parallel and batches of plates were
not changed throughout the
study, a bias seems to be unlikely. The low
discriminatory ability
of the B31 IgM test can be explained by the lack
of OspC, which
is one of the most immunodominant proteins for the early
immune
response in patients with LB (
12,
13,
17,
48).
Sensitivities for individual study groups.
For the sera from
patients with EM and the NB II group, the best results were obtained
with PKo. For the sera from patients with EM, this can be explained by
the predominance of B. afzelii strains in skin lesions
(8, 9, 44, 47). The sera from the NB II study group were
selected on the basis of the criterion of a specific IgG CSF/serum
index of >2.0, and this index was determined by a PKo-based ELISA.
Therefore, the high sensitivity of the PKo ELISA in the current study
could result from this selection. On the other hand, for sera from the
NB I group (selection criterion, isolate from CSF), the sensitivities
of the PKo, PBi, and PKa2 ELISAs were very similar, with the PKa2 ELISA
showing a slightly higher sensitivity. However, in other studies sera
from patients with neurological disorders were preferentially reactive
with B. garinii (1, 26, 42), and strains of this
species have been isolated most frequently from CSF (8, 40,
44). All sera from patients with ACA were positive in all IgG
ELISAs, suggesting that the source of antigen is not critical for the
detection of LB in sera from patients with late-stage LB. For the group
of forest workers, a relatively high frequency of asymptomatic and previous infections can be assumed. At least 40% of their sera were
positive by all IgG ELISAs (compared to 8% for the group of blood
donors).
Correlation of OD values of different ELISAs.
For several sera
from patients with ACA as well as from forest workers, a markedly
stronger IgG reactivity with PKo was found (in comparison to those
obtained with the other strains). Therefore, the correlations between
PKo and all other strains were lower than the correlations among these
other strains (Fig. 4). However, the good correlation of PBi or PKa2
versus PKo for the NB groups may indicate that the strain discrepancy
observed in forest workers and patients with ACA is not biased by the
coating conditions of the ELISA solid phase. WB of several selected
serum specimens with discrepant reactivities revealed that this
preference of PKo was mostly caused by strong reactivity with p17 (Fig.
6E to F). This is a highly immunogenic protein of strain PKo (17, 46) which is apparently not expressed by the other three strains. For sera from patients with EM lesions, frequent IgG reactivity with
several proteins unique for PKo was demonstrated previously (17) (other B. afzelii strains have not been
tested so far). For the NB groups, the somewhat lower correlations
between B31 and each of the other three strains could be explained by
the lack of OspC in B31. Thus, sera primarily recognizing OspC showed less intense reactivities with B31. However, a few individual serum
specimens also showed discrepant ELISA reactivities caused by the
discrepant recognition of other antigens (for example, Fig. 6C and D).
Since OspC is one of the most immunodominant antigens in the early
immune response, lower correlations of B31 with the other
strains were
especially marked in IgM ELISAs (Fig.
5).
B. burgdorferi sensu stricto B31 tends to lose OspC after many passages, contributing
to its poor IgM sensitivity in all stages of LB, while strain
PKa2
expressing OspC shows a considerably higher IgM sensitivity.
This view
is consistent with a statement of U.S. health authorities
that
high-passage isolates of B31 lacking OspC are not recommended
for use
in serological tests for LB (
10).
For two serum samples selected due to discrepant reactivities in IgM
ELISAs, preferential reactivity with OspC of PBi could
be demonstrated
by WB (Fig.
6A and B). In a study by Mathiesen
et al. (
24),
the OspC of a
B. garinii strain was also more sensitive
in
WB than the OspCs of a
B. burgdorferi sensu stricto strain
and a
B. afzelii strain.
In the current study, the highest correlations in both IgG and IgM
ELISAs were observed between PBi and PKa2 in all study
groups. Although
these two strains belong to different species
and some
well-characterized proteins are rather heterogeneous
(
20,
29,
38,
43), immune reactivity with other presumably
highly conserved
antigens may be compensatory.
Clinical manifestations versus asymptomatic infection; what do
elevated specific IgG concentrations mean?
In general, specific
IgG concentrations increase with the duration of LB (18, 34)
(at least during the first months, if no antibiotic treatment is
performed). Usually, in late stages, high antibody concentrations are
observed. Unfortunately, however, especially in late LB, antibody
activity can persist over years even if successful treatment is
performed (14, 36). Thus, only limited information about the
activity can be achieved by monitoring the specific IgG concentrations
over the course of the disease. As already mentioned, many sera from
the healthy forest workers had stronger IgG reactivities with PKo than
with the other strains tested. This observation led to the assumption that assays with strains other than PKo might be more informative with
regard to the activity of the disease. Therefore, the percentage of
sera with OD values greater than a few exemplarily chosen levels were
determined for all patients with LB as well as for the forest workers
(Table 3). Significantly more sera from patients with LB than from
forest workers reached OD values greater than these levels in tests
with PBi, PKa2, and B31. With PKo, no significant differences were
detected. Thus, it could be shown that highly elevated antibody
concentrations are more likely to be associated with clinical
manifestations of disease than with asymptomatic or passed infection if
strains other than PKo are used. However, with respect to this
evaluation it should be mentioned that the prevalences of clinical
manifestations of LB in all patients with LB (n = 222)
selected for this study does not represent the actual prevalences of
manifestations of LB in the general population (e.g., EM is more common
than NB).
A combination of a PKo assay and a test based on PBi or PKa2 might be
most informative. For example, one assay could be used
for screening
and the other could be used for confirmation. The
combination of strong
PKo reactivity and weak non-PKo reactivity
might be consistent with ACA
or asymptomatic infection. If these
results were obtained, for example,
for a patient who is suffering
from an atypical neurological disorder,
B. burgdorferi sensu lato
presumably might not be causative.
However, these are unproven
suggestions, and interpretation needs to be
specified in detail.
This might be possible only in specialized
laboratories and would
require intensive communication between
physicians in the laboratories
and in hospitals or offices.
Conclusion.
In routine testing results can vary considerably
among different laboratories. Besides differences in antigen
preparation and test performance, this variation may result from the
use of different species of B. burgdorferi sensu lato. By
generalizing the results of the current study, it might be assumed that
these variations occur mainly between B. afzelii-based tests
on the one hand and assays with B. burgdorferi sensu stricto
or B. garinii on the other hand. However, regional
differences may further influence test results. Furthermore, variations
in the level of expression or a complete lack of expression of
immunodominant antigens such as OspC may be critical. Since the OGP
extract of PKo was the most sensitive in this study but extracts of the
other strains were better able to differentiate between active disease
and asymptomatic infection, we suggest that a combination of a test
with a B. afzelii strain and another test with a B. garinii strain (high sensitivity with sera from patients with NB)
might be most informative. If WB with PKo were used, mere detection of
a p17 band without other significant bands might be grounds for
suspicion of previous LB. Further investigations are necessary to
elucidate this assumption.
 |
ACKNOWLEDGMENTS |
We thank Heidi Loy-Weigand, Gisela Lehnert, Manfred Klotz, and
Klaus Ruth for excellent technical assistance, Andreas
Hofmann-Lerner and Sigrun Burkert for collecting sera, and Sofia
Reinecke for help with the manuscript.
We thank Gotthard Ruckdeschel and Jürgen Heesemann for generous
support of this work.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Max von
Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie
der Ludwig-Maximilians-Universität München,
Pettenkoferstr. 9a, D-80336 Munich, Germany. Phone: 0049-89-51605225. Fax: 0049-89-51604757. E-mail:
hauser{at}m3401.mpk.med.uni-muenchen.de.
 |
REFERENCES |
| 1.
|
Assous, M. V.,
D. Postic,
G. Paul,
P. Nevot, and G. Baranton.
1993.
Western blot analysis of sera from Lyme borreliosis patients according to the genomic species of the Borrelia strains used as antigens.
Eur. J. Clin. Microbiol. Infect. Dis.
12:261-268[Medline].
|
| 2.
|
Baranton, G.,
D. Postic,
I. Saint Girons,
P. Boerlin,
J.-C. Piffaretti,
M. Assous, and P. A. D. Grimont.
1992.
Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis.
Int. J. Syst. Bacteriol.
42:378-383[Abstract/Free Full Text].
|
| 3.
|
Bergström, S.,
A. Sjöstedt,
L. Dotevall,
B. Kaijser,
B. Ekstrand-Hammarström,
C. Wallberg,
G. Skogman, and A. G. Barbour.
1991.
Diagnosis of Lyme borreliosis by an enzyme immunoassay detecting immunoglobulin G reactive to purified Borrelia burgdorferi cell components.
Eur. J. Clin. Microbiol. Infect. Dis.
10:422-427[Medline].
|
| 4.
|
Bradford, M.
1976.
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Anal. Biochem.
72:248-254[Medline].
|
| 5.
|
Bruckbauer, H.,
V. Preac-Mursic,
R. Fuchs, and B. Wilske.
1992.
Cross-reactive proteins of Borrelia burgdorferi.
Eur. J. Clin. Microbiol. Infect. Dis.
11:1-9[Medline].
|
| 6.
|
Bunikis, J.,
B. Olsen,
G. Westman, and S. Bergström.
1995.
Variable serum immunoglobulin responses against different Borrelia burgdorferi sensu lato species in a population at risk for and patients with Lyme disease.
J. Clin. Microbiol.
33:1473-1478[Abstract].
|
| 7.
|
Burkert, S.,
D. Rössler,
P. Münchhoff, and B. Wilske.
1996.
Development of enzyme-linked immunosorbent assays using recombinant borrelial antigens for serodiagnosis of Borrelia burgdorferi infection.
Med. Microbiol. Immunol.
185:49-57[Medline].
|
| 8.
|
Busch, U.,
C. Hizo-Teufel,
R. Boehmer,
V. Fingerle,
H. Nitschko,
B. Wilske, and V. Preac-Mursic.
1996.
Three species of Borrelia burgdorferi sensu lato (B. burgdorferi sensu stricto, B. afzelii and B. garinii) identified from cerebrospinal fluid isolates by pulsed-field gel electrophoresis and PCR.
J. Clin. Microbiol.
34:1072-1078[Abstract].
|
| 9.
|
Canica, M. M.,
F. Nato,
L. Du Merle,
J. C. Mazie,
G. Baranton, and D. Postic.
1993.
Monoclonal antibodies for identification of Borrelia afzelii sp. nov. associated with late cutaneous manifestations of Lyme borreliosis.
Scand. J. Infect. Dis.
25:441-448[Medline].
|
| 10.
|
Centers for Disease Control and Prevention and Association of State and Territorial Public Health Laboratory Directors.
1994.
Proceedings of the Second National Conference on Serologic Diagnosis of Lyme Disease.
Centers for Disease Control and Prevention, Fort Collins, Colo.
|
| 11.
|
Dawson-Saunders, B., and R. G. Trapp.
1990.
Basic and clinical biostatistics.
Appleton & Lange, San Mateo, Calif.
|
| 12.
|
Dressler, F.,
J. A. Whalen,
B. N. Reinhardt, and A. C. Steere.
1993.
Western blotting in the serodiagnosis of Lyme disease.
J. Infect. Dis.
167:392-400[Medline].
|
| 13.
|
Engström, S. M.,
E. Shoop, and R. C. Johnson.
1995.
Immunoblot interpretation criteria for serodiagnosis of early Lyme disease.
J. Clin. Microbiol.
33:419-427[Abstract].
|
| 14.
|
Feder, H. M., Jr.,
M. A. Gerber,
S. W. Luger, and R. W. Ryan.
1992.
Persistence of serum antibodies to Borrelia burgdorferi in patients treated for Lyme disease.
Clin. Infect. Dis.
15:788-793[Medline].
|
| 15.
|
Fingerle, V.,
H. Bergmeister,
G. Liegl,
E. Vanek, and B. Wilske.
1994.
Prevalence of Borrelia burgdorferi sensu lato in Ixodes ricinus in southern Germany.
J. Spiroch. Tick Dis.
1:41-45.
|
| 16.
|
Hansen, K.,
K. Pii, and A.-M. Lebech.
1991.
Improved immunoglobulin M serodiagnosis in Lyme borreliosis by using a µ-capture enzyme-linked immunosorbent assay with biotinylated Borrelia burgdorferi flagella.
J. Clin. Microbiol.
29:166-173[Abstract/Free Full Text].
|
| 17.
|
Hauser, U.,
G. Lehnert,
R. Lobentanzer, and B. Wilske.
1997.
Interpretation criteria for standardized Western blots of three European species of Borrelia burgdorferi sensu lato.
J. Clin. Microbiol.
35:1433-1444[Abstract].
|
| 18.
|
Herzer, P.
1990.
Lyme-Borreliose. Epidemiologie, Ätiologie, Diagnostik, Klinik und Therapie.
Steinkopff, Darmstadt, Germany.
|
| 19.
|
Hofmann, A. E. A.,
V. Fingerle,
U. Hauser,
K. Rieth, and B. Wilske.
1994.
Epidemiology of Lyme borreliosis in southern Germany during the years 1987 through 1990.
J. Spiroch. Tick Dis.
1:90-97.
|
| 20.
|
Jauris-Heipke, S.,
G. Liegl,
V. Preac-Mursic,
D. Rößler,
E. Schwab,
E. Soutschek,
G. Will, and B. Wilske.
1995.
Molecular analysis of genes encoding outer surface protein C (OspC) of Borrelia burgdorferi sensu lato: relationship to ospA genotype and evidence of lateral gene exchange of ospC.
J. Clin. Microbiol.
33:1860-1866[Abstract].
|
| 21.
|
Kyhse-Andersen, J.
1984.
Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose.
J. Biochem. Biophys. Methods
10:203-209[Medline].
|
| 22.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[Medline].
|
| 23.
|
Magnarelli, L. A.,
J. F. Anderson,
R. C. Johnson,
R. B. Nadelman, and G. P. Wormser.
1994.
Comparison of different strains of Borrelia burgdorferi sensu lato used as antigens in enzyme-linked immunosorbent assays.
J. Clin. Microbiol.
32:1154-1158[Abstract/Free Full Text].
|
| 24.
|
Mathiesen, M. J.,
K. Hansen,
N. Axelsen,
L. Halkier-Sorensen, and M. Theisen.
1996.
Analysis of the human antibody response to outer surface protein C (OspC) of Borrelia burgdorferi sensu stricto, B. garinii, and B. afzelii.
Med. Microbiol. Immunol.
185:121-129[Medline].
|
| 25.
|
Münchhoff, P.,
B. Wilske,
V. Preac-Mursic, and G. Schierz.
1987.
Antibodies against Borrelia burgdorferi in Bavarian forest workers.
Zentralbl. Bakteriol. Mikrobiol. Hyg. A
263:412-419.
|
| 26.
|
Norman, G. L.,
J. M. Antig,
G. Bigaignon, and W. R. Hogrefe.
1996.
Serodiagnosis of Lyme borreliosis by Borrelia burgdorferi sensu stricto, B. garinii, and B. afzelii Western blots (immunoblots).
J. Clin. Microbiol.
34:1732-1738[Abstract].
|
| 27.
|
Peters, H.,
K. Ruth, and H.-D. Dopatka.
1993.
Einpunktquantifizierung zur Bestimmung von Borrelia-spezifischen IgG-Antikörpern in einem neuen ELISA.
Lab. Med.
16:248-249.
|
| 28.
|
Preac-Mursic, V.,
B. Wilske, and G. Schierz.
1986.
European Borrelia burgdorferi isolated from humans and ticks: culture conditions and antibiotic susceptibility.
Zentralbl. Bakteriol. Mikrobiol. Hyg. A
263:112-118.
|
| 29.
|
Rössler, D.,
H. Eiffert,
S. Jauris-Heipke,
G. Lehnert,
V. Preac-Mursic,
J. Teepe,
T. Schlott,
E. Soutschek, and B. Wilske.
1995.
Molecular and immunological characterization of the p83/100 protein of various Borrelia burgdorferi sensu lato strains.
Med. Microbiol. Immunol.
184:23-32[Medline].
|
| 30.
|
Schwan, T. G.,
M. E. Schrumpf,
R. H. Karstens,
J. R. Clover,
J. Wong,
M. Daugherty,
M. Struthers, and P. A. Rosa.
1993.
Distribution and molecular analysis of Lyme disease spirochetes, Borrelia burgdorferi, isolated from ticks throughout California.
J. Clin. Microbiol.
31:3096-3108[Abstract/Free Full Text].
|
| 31.
|
Simpson, W. J.,
M. E. Schrumpf, and T. G. Schwan.
1990.
Reactivity of human Lyme borreliosis sera with a 39-kilodalton antigen specific to Borrelia burgdorferi.
J. Clin. Microbiol.
28:1329-1337[Abstract/Free Full Text].
|
| 32.
|
Stanek, G.,
N. Satz,
F. Strle, and B. Wilske.
1993.
Epidemiology of Lyme borreliosis, p. 358-370.
In
K. Weber, and W. Burgdorfer (ed.), Aspects of Lyme borreliosis. Springer, Berlin, Germany.
|
| 33.
|
Steere, A. C.
1989.
Medical progress Lyme disease.
N. Engl. J. Med.
321:586-596[Abstract].
|
| 34.
|
Steere, A. C.,
R. L. Grodzicki,
A. N. Kornblatt,
J. E. Craft,
A. G. Barbour,
W. Burgdorfer,
G. P. Schmid,
E. Johnson, and S. E. Malawista.
1983.
The spirochetal etiology of Lyme disease.
N. Engl. J. Med.
308:733-740[Abstract].
|
| 35.
|
Van Dam, A. P.,
H. Kuiper,
K. Vos,
A. Widjojokusumo,
B. M. De Jongh,
L. Spanjaard,
A. C. P. Ramselaar,
M. D. Kramer, and J. Dankert.
1993.
Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis.
Clin. Infect. Dis.
17:708-717[Medline].
|
| 36.
|
Weber, K.,
V. Preac-Mursic,
U. Neubert,
R. Thurmayr,
P. Herzer,
B. Wilske,
G. Schierz, and W. Marget.
1988.
Antibiotic therapy of early European Lyme borreliosis and acrodermatitis chronica atrophicans.
Ann. N. Y. Acad. Sci.
539:324-345[Medline].
|
| 37.
|
Weber, K.,
B. Wilske,
V. Preac-Mursic, and R. Thurmayr.
1993.
Azithromycin versus penicillin V for the treatment of early Lyme borreliosis.
Infection
21:367-372[Medline].
|
| 38.
|
Will, G.,
S. Jauris-Heipke,
E. Schwab,
U. Busch,
D. Rössler,
E. Soutschek,
B. Wilske, and V. Preac-Mursic.
1995.
Sequence analysis of ospA genes shows homogeneity within Borrelia burgdorferi sensu stricto and Borrelia afzelii strains but reveals major subgroups within the Borrelia garinii species.
Med. Microbiol. Immunol.
184:73-80[Medline].
|
| 39.
|
Wilske, B.,
L. Bader,
H. W. Pfister, and V. Preac-Mursic.
1991.
Diagnostik der Lyme-Neuroborreliose (Nachweis der intrathekalen Antikörperbildung).
Fortschr. Med.
109:441-446[Medline].
|
| 40.
|
Wilske, B.,
U. Busch,
H. Eiffert,
V. Fingerle,
H.-W. Pfister,
D. Rössler, and V. Preac-Mursic.
1996.
Diversity of OspA and OspC among cerebrospinal fluid isolates of Borrelia burgdorferi sensu lato from patients with neuroborreliosis in Germany.
Med. Microbiol. Immunol.
184:195-201[Medline].
|
| 41.
|
Wilske, B.,
V. Fingerle,
P. Herzer,
A. Hofmann,
G. Lehnert,
H. Peters,
H.-W. Pfister,
V. Preac-Mursic,
E. Soutschek, and K. Weber.
1993.
Recombinant immunoblot in the serodiagnosis of Lyme borreliosis.
Med. Microbiol. Immunol.
182:255-270[Medline].
|
| 42.
|
Wilske, B.,
V. Fingerle,
V. Preac-Mursic,
S. Jauris-Heipke,
A. Hofmann,
H. Loy,
H.-W. Pfister,
D. Rössler, and E. Soutschek.
1994.
Immunoblot using recombinant antigens derived from different genospecies of Borrelia burgdorferi sensu lato.
Med. Microbiol. Immunol.
183:43-59[Medline].
|
| 43.
|
Wilske, B.,
S. Jauris-Heipke,
R. Lobentanzer,
I. Pradel,
V. Preac-Mursic,
D. Roessler,
E. Soutschek, and R. C. Johnson.
1995.
Phenotypic analysis of the outer surface protein C (OspC) of Borrelia burgdorferi sensu lato by monoclonal antibodies: relationship to genospecies and OspA serotype.
J. Clin. Microbiol.
33:103-109[Abstract].
|
| 44.
|
Wilske, B.,
V. Preac-Mursic,
U. B. Göbel,
B. Graf,
S. Jauris-Heipke,
E. Soutschek,
E. Schwab, and G. Zumstein.
1993.
An OspA serotyping system for Borrelia burgdorferi based on reactivity with monoclonal antibodies and OspA sequence analysis.
J. Clin. Microbiol.
31:340-350[Abstract/Free Full Text].
|
| 45.
|
Wilske, B.,
V. Preac-Mursic,
S. Jauris,
A. Hofmann,
I. Pradel,
E. Soutschek,
E. Schwab,
G. Will, and G. Wanner.
1993.
Immunological and molecular polymorphisms of OspC, an immunodominant major outer surface protein of Borrelia burgdorferi.
Infect. Immun.
61:2182-2191[Abstract/Free Full Text].
|
| 46.
|
Wilske, B.,
V. Preac-Mursic,
G. Schierz,
W. Gueye,
P. Herzer, and K. Weber.
1988.
Immunochemical analysis of the immune response in late manifestations of Lyme borreliosis.
Zentralbl. Bakteriol. Mikrobiol. Hyg. A
267:549-558.
|
| 47.
|
Wilske, B.,
V. Preac-Mursic,
G. Schierz,
R. Kühbeck,
A. G. Barbour, and M. Kramer.
1988.
Antigenic variability of Borrelia burgdorferi.
Ann. N. Y. Acad. Sci.
539:126-143[Medline].
|
| 48.
| Wilske, B., V. Preac-Mursic, G. Schierz, G. Liegl, and
W. Gueye. 1989. Detection of IgM and IgG antibodies to Borrelia
burgdorferi using different strains as antigen. Zentralbl. Bakteriol.
18(Suppl.):299-309.
|
| 49.
|
Wilske, B.,
G. Schierz,
V. Preac-Mursic,
K. Weber,
H. W. Pfister, and K. Einhäupl.
1984.
Serological diagnosis of erythema migrans disease and related disorders.
Infection
12:331-337[Medline].
|
Journal of Clinical Microbiology, February 1998, p. 427-436, Vol. 36, No. 2
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Mavin, S, Evans, R, Milner, R M, Chatterton, J M W, Ho-Yen, D O
(2009). Local Borrelia burgdorferi sensu stricto and Borrelia afzelii strains in a single mixed antigen improves western blot sensitivity. J. Clin. Pathol.
62: 552-554
[Abstract]
[Full Text]
-
Stubs, G., Fingerle, V., Wilske, B., Gobel, U. B., Zahringer, U., Schumann, R. R., Schroder, N. W. J.
(2009). Acylated Cholesteryl Galactosides Are Specific Antigens of Borrelia Causing Lyme Disease and Frequently Induce Antibodies in Late Stages of Disease. J. Biol. Chem.
284: 13326-13334
[Abstract]
[Full Text]
-
Blanc, F., Jaulhac, B., Fleury, M., de Seze, J., de Martino, S. J., Remy, V., Blaison, G., Hansmann, Y., Christmann, D., Tranchant, C.
(2007). Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients. Neurology
69: 953-958
[Abstract]
[Full Text]
-
Mavin, S., Milner, R. M., Evans, R., Chatterton, J. M. W., Joss, A. W. L., Ho-Yen, D. O.
(2007). The use of local isolates in Western blots improves serological diagnosis of Lyme disease in Scotland. J Med Microbiol
56: 47-51
[Abstract]
[Full Text]
-
Marangoni, A., Sambri, V., Accardo, S., Cavrini, F., Mondardini, V., Moroni, A., Storni, E., Cevenini, R.
(2006). A Decrease in the Immunoglobulin G Antibody Response against the VlsE Protein of Borrelia burgdorferi Sensu Lato Correlates with the Resolution of Clinical Signs in Antibiotic-Treated Patients with Early Lyme Disease. CVI
13: 525-529
[Abstract]
[Full Text]
-
Aguero-Rosenfeld, M. E., Wang, G., Schwartz, I., Wormser, G. P.
(2005). Diagnosis of Lyme Borreliosis. Clin. Microbiol. Rev.
18: 484-509
[Abstract]
[Full Text]
-
Marangoni, A., Sparacino, M., Cavrini, F., Storni, E., Mondardini, V., Sambri, V., Cevenini, R.
(2005). Comparative evaluation of three different ELISA methods for the diagnosis of early culture-confirmed Lyme disease in Italy. J Med Microbiol
54: 361-367
[Abstract]
[Full Text]
-
Ornstein, K., Ostberg, Y., Bunikis, J., Noppa, L., Berglund, J., Norrby, R., Bergstrom, S.
(2002). Differential Immune Response to the Variable Surface Loop Antigen of P66 of Borrelia burgdorferi Sensu Lato Species in Geographically Diverse Populations of Lyme Borreliosis Patients. CVI
9: 1382-1384
[Abstract]
[Full Text]
-
Liang, F. T., Nelson, F. K., Fikrig, E.
(2002). DNA Microarray Assessment of Putative Borrelia burgdorferi Lipoprotein Genes. Infect. Immun.
70: 3300-3303
[Abstract]
[Full Text]
-
Heikkila, T., Seppala, I., Saxen, H., Panelius, J., Yrjanainen, H., Lahdenne, P.
(2002). Species-Specific Serodiagnosis of Lyme Arthritis and Neuroborreliosis Due to Borrelia burgdorferi Sensu Stricto, B. afzelii, and B. garinii by Using Decorin Binding Protein A. J. Clin. Microbiol.
40: 453-460
[Abstract]
[Full Text]
-
Piacentino, J D, Schwartz, B S
(2002). Occupational risk of Lyme disease: an epidemiological review. Occup. Environ. Med.
59: 75-84
[Abstract]
[Full Text]
-
Ornstein, K., Berglund, J., Nilsson, I., Norrby, R., Bergström, S.
(2001). Characterization of Lyme Borreliosis Isolates from Patients with Erythema Migrans and Neuroborreliosis in Southern Sweden. J. Clin. Microbiol.
39: 1294-1298
[Abstract]
[Full Text]
-
Kouzmitcheva, G. A., Petrenko, V. A., Smith, G. P.
(2001). Identifying Diagnostic Peptides for Lyme Disease through Epitope Discovery. CVI
8: 150-160
[Abstract]
[Full Text]
-
Wang, G., van Dam, A. P., Schwartz, I., Dankert, J.
(1999). Molecular Typing of Borrelia burgdorferi Sensu Lato: Taxonomic, Epidemiological, and Clinical Implications. Clin. Microbiol. Rev.
12: 633-653
[Abstract]
[Full Text]
-
Hauser, U., Lehnert, G., Wilske, B.
(1999). Validity of Interpretation Criteria for Standardized Western Blots (Immunoblots) for Serodiagnosis of Lyme Borreliosis Based on Sera Collected throughout Europe. J. Clin. Microbiol.
37: 2241-2247
[Abstract]
[Full Text]
-
Masters, E. J., Kirkland, K. B., Dennis, D. T.
(1998). Erythema Migrans in the South. Arch Intern Med
158: 2162-2165
[Full Text]
-
Masters, E., Granter, S., Duray, P., Cordes, P.
(1998). Physician-Diagnosed Erythema Migrans and Erythema Migrans-like Rashes Following Lone Star Tick Bites. Arch Dermatol
134: 955-960
[Abstract]
[Full Text]